Keyword: Eylea

Regeneron

Regeneron's Q3 profit beat snaps bad news streak

Regeneron capped a rough four weeks last Friday with news that sarilumab, its anti-inflammatory blockbuster hopeful, had been knocked aside by the FDA. But this Friday, it gave investors something to cheer about with Q3 profit that beat expectations.